Literature DB >> 34035728

The Future of Treatment for Nonalcoholic Steatohepatitis.

Michael Charlton1.   

Abstract

Entities:  

Year:  2020        PMID： 34035728      PMCID： PMC8132637     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  5 in total

1.  Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.

Authors:  Eric J Lawitz; Angie Coste; Fred Poordad; Naim Alkhouri; Nicole Loo; Bryan J McColgan; Jacqueline M Tarrant; Tuan Nguyen; Ling Han; Chuhan Chung; Adrian S Ray; John G McHutchison; G Mani Subramanian; Robert P Myers; Michael S Middleton; Claude Sirlin; Rohit Loomba; Edna Nyangau; Mark Fitch; Kelvin Li; Marc Hellerstein
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-26       Impact factor: 11.382

2.  Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

Authors:  Zobair M Younossi; Vlad Ratziu; Rohit Loomba; Mary Rinella; Quentin M Anstee; Zachary Goodman; Pierre Bedossa; Andreas Geier; Susanne Beckebaum; Philip N Newsome; David Sheridan; Muhammad Y Sheikh; James Trotter; Whitfield Knapple; Eric Lawitz; Manal F Abdelmalek; Kris V Kowdley; Aldo J Montano-Loza; Jerome Boursier; Philippe Mathurin; Elisabetta Bugianesi; Giuseppe Mazzella; Antonio Olveira; Helena Cortez-Pinto; Isabel Graupera; David Orr; Lise Lotte Gluud; Jean-Francois Dufour; David Shapiro; Jason Campagna; Luna Zaru; Leigh MacConell; Reshma Shringarpure; Stephen Harrison; Arun J Sanyal
Journal:  Lancet       Date:  2019-12-05       Impact factor: 79.321

3.  Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Zobair M Younossi; Rohit Loomba; Mary E Rinella; Elisabetta Bugianesi; Giulio Marchesini; Brent A Neuschwander-Tetri; Lawrence Serfaty; Francesco Negro; Stephen H Caldwell; Vlad Ratziu; Kathleen E Corey; Scott L Friedman; Manal F Abdelmalek; Stephen A Harrison; Arun J Sanyal; Joel E Lavine; Philippe Mathurin; Michael R Charlton; Naga P Chalasani; Quentin M Anstee; Kris V Kowdley; Jacob George; Zachary D Goodman; Keith Lindor
Journal:  Hepatology       Date:  2018-07       Impact factor: 17.425

4.  Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

Authors:  Vlad Ratziu; Stephen A Harrison; Sven Francque; Pierre Bedossa; Philippe Lehert; Lawrence Serfaty; Manuel Romero-Gomez; Jérôme Boursier; Manal Abdelmalek; Steve Caldwell; Joost Drenth; Quentin M Anstee; Dean Hum; Remy Hanf; Alice Roudot; Sophie Megnien; Bart Staels; Arun Sanyal
Journal:  Gastroenterology       Date:  2016-02-11       Impact factor: 22.682

5.  Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.

Authors:  Vlad Ratziu; Arun Sanyal; Stephen A Harrison; Vincent Wai-Sun Wong; Sven Francque; Zachary Goodman; Guruprasad P Aithal; Kris V Kowdley; Star Seyedkazemi; Laurent Fischer; Rohit Loomba; Manal F Abdelmalek; Frank Tacke
Journal:  Hepatology       Date:  2020-07-21       Impact factor: 17.425
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.